MLH1 and cancer: This is a strikingly young age for the development of a ‘sporadic’ MSI cancer through biallelic methylation of MLH1 (Ward et al, 2001), and raises the possibility that MYH mutation has somehow either facilitated methylation, or acted synergistically with MLH1 loss to more rapidly drive tumour progression.